Zydus Cadila, a pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and In a release, the companies noted:
The collaboration combines Pieris' drug discovery and early development capabilities with Zydus' expertise in biologics development, regulatory affairs and biologics manufacturing. Under the terms of the agreement, Zydus will take the lead in advancing Anticalin drug candidates through formal pre-clinical development and into clinical development, undertaking drug development in accordance with ICH guidelines. Zydus has been granted exclusive marketing rights in
The most advanced program in the collaboration is PRS-110, an Anticalin specific for c-Met, a target becoming increasingly validated across a broad spectrum of tumors. PRS-110, which is a pure antagonist due to its monovalent target engagement, has demonstrated the ability to inhibit both ligand-dependent and - independent c-Met activity in a variety of animal models. Through this collaborative model, the companies seek to develop candidates to proof-of-concept and will explore out-licensing opportunities in Pieris' territories at the appropriate time. The companies will share licensing revenues on mutually agreed-upon terms.
((Comments on this story may be sent to firstname.lastname@example.org))
Zydus Cadila, a pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and
In a release, the companies noted: